DE3854741D1 - Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen. - Google Patents
Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.Info
- Publication number
- DE3854741D1 DE3854741D1 DE3854741T DE3854741T DE3854741D1 DE 3854741 D1 DE3854741 D1 DE 3854741D1 DE 3854741 T DE3854741 T DE 3854741T DE 3854741 T DE3854741 T DE 3854741T DE 3854741 D1 DE3854741 D1 DE 3854741D1
- Authority
- DE
- Germany
- Prior art keywords
- autoantigens
- oral administration
- autoimmune diseases
- treating autoimmune
- autoimmune disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Rehabilitation Therapy (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Marine Sciences & Fisheries (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6573487A | 1987-06-24 | 1987-06-24 | |
PCT/US1988/002139 WO1988010120A1 (en) | 1987-06-24 | 1988-06-24 | Treatment of autoimmune diseases by oral administration of autoantigens |
Publications (3)
Publication Number | Publication Date |
---|---|
DE3854741D1 true DE3854741D1 (de) | 1996-01-11 |
DE3854741T2 DE3854741T2 (de) | 1996-04-18 |
DE3854741T3 DE3854741T3 (de) | 2002-08-14 |
Family
ID=22064733
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE3856566T Expired - Lifetime DE3856566T2 (de) | 1987-06-24 | 1988-06-24 | Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen |
DE3854741T Expired - Lifetime DE3854741T3 (de) | 1987-06-24 | 1988-06-24 | Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE3856566T Expired - Lifetime DE3856566T2 (de) | 1987-06-24 | 1988-06-24 | Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen |
Country Status (8)
Country | Link |
---|---|
EP (2) | EP0666080B1 (de) |
JP (1) | JP2512796B2 (de) |
AT (2) | ATE258065T1 (de) |
AU (1) | AU632991B2 (de) |
CA (1) | CA1336954C (de) |
DE (2) | DE3856566T2 (de) |
DK (1) | DK175666B1 (de) |
WO (1) | WO1988010120A1 (de) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843445A (en) * | 1987-06-24 | 1998-12-01 | Autoimmune, Inc. | Method of treating rheumatoid arthritis with type II collagen |
US5571499A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
US5641474A (en) * | 1987-06-24 | 1997-06-24 | Autoimmune, Inc. | Prevention of autoimmune diseases by aerosol administration of autoantigens |
US5849298A (en) * | 1987-06-24 | 1998-12-15 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of bovine myelin |
US5571500A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases through administration by inhalation of autoantigens |
US5869054A (en) * | 1987-06-24 | 1999-02-09 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of autoantigens |
US5645820A (en) * | 1987-06-24 | 1997-07-08 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
US6645504B1 (en) | 1987-06-24 | 2003-11-11 | Autoimmune Inc. | Bystander suppression of type I diabetes by oral administration of glucagon |
CA1340012C (en) * | 1987-08-17 | 1998-08-25 | Trustees Of Leland Stanford Jr. University | Peptide determinant associated with immunity |
MY107386A (en) * | 1988-11-03 | 1995-11-30 | Schering Corp | Method of preventing or reducing eosinophilia |
NO306996B1 (no) * | 1989-02-17 | 2000-01-24 | Bayer Ag | Isolert bukspyttkjerteloey-celle-(ICA)-antigen for in vitro- bruk |
IL89431A0 (en) * | 1989-02-27 | 1989-09-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of autoimmune diseases |
DE69031563T2 (de) * | 1989-07-14 | 1998-02-12 | Autoimmune, Inc., Lexington, Mass. | Behandlung der autoimmunen uveoretinitis in menschen |
AU642693B2 (en) * | 1989-12-20 | 1993-10-28 | Autoimmune, Inc. | Improved treatment of autoimmune diseases by aerosol administration of auto antigens |
US5620686A (en) * | 1990-09-28 | 1997-04-15 | British Technology Group Limited | Antigen-antibody conjugates |
ES2095956T3 (es) * | 1990-09-28 | 1997-03-01 | British Tech Group | Conjugados antigeno-anticuerpo. |
IL99699A (en) * | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
AU9023791A (en) * | 1990-10-15 | 1992-05-20 | Brigham And Women's Hospital | Treatment of autoimmune diseases by oral administration of autoantigens |
GB2251186A (en) * | 1990-12-04 | 1992-07-01 | Randall Neal Gatz | Polypeptide for use in treatment of autoimmune disease |
US6252040B1 (en) | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
US5817629A (en) | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
EP0705108A4 (de) * | 1993-06-02 | 1997-08-06 | Tvw Telethon Inst Child Health | Verwendung von kryptischen peptiden zur induktion immunologisches toleranz |
GB9319429D0 (en) | 1993-09-21 | 1993-11-03 | London Health Ass | Methods and products for controlling immune responses in mammals |
IL115766A0 (en) * | 1994-10-25 | 1996-01-19 | Immulogic Pharma Corp | Composition and treatment for multiple sclerosis |
US6379670B1 (en) | 1994-11-18 | 2002-04-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
US6251396B1 (en) | 1994-11-18 | 2001-06-26 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
US6488933B2 (en) | 1995-07-05 | 2002-12-03 | Yeda Research And Development Co. Ltd. | Preparations for the treatment of T cell mediated diseases |
US5856446A (en) * | 1995-07-07 | 1999-01-05 | Autoimmune Inc. | Method of treating rheumatoid arthritis with low dose type II collagen |
US5843462A (en) | 1995-11-30 | 1998-12-01 | Regents Of The University Of Minnesota | Diphtheria toxin epitopes |
BR9706922A (pt) * | 1996-01-05 | 1999-07-20 | Autoimmune Inc | Método para facilitar a remoção de membrana pericondrial de tecido de cartilagem vertebral não processado para remover proteoglicanos de tecido contendo colágeno tipo ii e para obter um produto contendo colágeno tipo ii |
WO1998032451A1 (en) * | 1997-01-24 | 1998-07-30 | Autoimmune, Inc. | Treatment of autoimmune disease using tolerization in combination with methotrexate |
US7097845B2 (en) | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
EP1037663A2 (de) | 1997-12-16 | 2000-09-27 | Regents Of The University Of Minnesota | Verfahren zur behandlung unerwünschter immunantworten |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
WO2000005250A1 (en) | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
WO2001068124A2 (en) | 2000-03-15 | 2001-09-20 | The Brigham And Women's Hospital, Inc. | Suppression of vascular disorders by mucosal administration of heat shock protein peptides |
US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
US20030191063A1 (en) | 2000-08-21 | 2003-10-09 | Wraith David Cameron | Peptide selection method |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
MXPA04005433A (es) | 2001-12-04 | 2004-10-11 | Teva Pharma | Proceso para la medicion de la potencia de acetato de glatiramero. |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
EP1641488B1 (de) | 2003-06-23 | 2011-03-30 | Biotech Tools S.A. | Epitop-zusammensetzung zur enterischen verabreichung hergestellt durch hydrolyse von antigenen strukturen mit chymotrypsin |
WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3989819A (en) * | 1969-03-05 | 1976-11-02 | American Cyanamid Company | Process for separating proteins from central nervous system tissue and treating experimentally induced demyelinating diseases |
US4350682A (en) † | 1979-05-11 | 1982-09-21 | Lescarden Ltd. | Cartilage extraction processes and products |
ATE128627T1 (de) † | 1986-06-30 | 1995-10-15 | Massachusetts Inst Technology | Immunomodulare mittel und deren verwendung. |
CA1340012C (en) † | 1987-08-17 | 1998-08-25 | Trustees Of Leland Stanford Jr. University | Peptide determinant associated with immunity |
GB8803881D0 (en) * | 1988-02-19 | 1988-03-23 | Traqson Ltd | Novel photoactive compounds processes for their production & intermediates thereof |
AU3320089A (en) * | 1988-04-20 | 1989-10-26 | Hartech (Australia) Pty. Ltd. | Portable traffic lights |
-
1988
- 1988-06-24 AU AU20797/88A patent/AU632991B2/en not_active Expired
- 1988-06-24 AT AT95102528T patent/ATE258065T1/de not_active IP Right Cessation
- 1988-06-24 AT AT88906457T patent/ATE130762T1/de not_active IP Right Cessation
- 1988-06-24 DE DE3856566T patent/DE3856566T2/de not_active Expired - Lifetime
- 1988-06-24 CA CA000570406A patent/CA1336954C/en not_active Expired - Fee Related
- 1988-06-24 EP EP95102528A patent/EP0666080B1/de not_active Expired - Lifetime
- 1988-06-24 WO PCT/US1988/002139 patent/WO1988010120A1/en active IP Right Grant
- 1988-06-24 DE DE3854741T patent/DE3854741T3/de not_active Expired - Lifetime
- 1988-06-24 JP JP63506040A patent/JP2512796B2/ja not_active Expired - Lifetime
- 1988-06-24 EP EP88906457A patent/EP0359783B2/de not_active Expired - Lifetime
-
1989
- 1989-12-20 DK DK198906516A patent/DK175666B1/da not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA1336954C (en) | 1995-09-12 |
EP0359783B1 (de) | 1995-11-29 |
WO1988010120A1 (en) | 1988-12-29 |
JPH02503919A (ja) | 1990-11-15 |
AU632991B2 (en) | 1993-01-21 |
DK651689D0 (da) | 1989-12-20 |
EP0666080A1 (de) | 1995-08-09 |
DK651689A (da) | 1990-02-26 |
DE3856566T2 (de) | 2004-06-24 |
EP0359783B2 (de) | 2002-04-17 |
DK175666B1 (da) | 2005-01-10 |
EP0666080B1 (de) | 2004-01-21 |
EP0359783A4 (de) | 1990-06-27 |
DE3854741T2 (de) | 1996-04-18 |
AU2079788A (en) | 1989-01-19 |
DE3854741T3 (de) | 2002-08-14 |
ATE130762T1 (de) | 1995-12-15 |
ATE258065T1 (de) | 2004-02-15 |
EP0359783A1 (de) | 1990-03-28 |
JP2512796B2 (ja) | 1996-07-03 |
DE3856566D1 (de) | 2004-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3854741D1 (de) | Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen. | |
ATE319474T1 (de) | Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen | |
PT627933E (pt) | Supressao "bystander" de doencas autoimunes | |
ATE157257T1 (de) | Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen | |
DK0430474T3 (da) | Præparater med vedvarende frigivelse til behandling af periodontal sygdom | |
DE69033487D1 (de) | Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol | |
ATE107508T1 (de) | Verwendung von nalmefen oder naltrexon bei der behandlung von autoimmunerkrankungen. | |
DE3873855D1 (de) | Mischung von cholecalciferol-derivaten fuer die behandlung von nierenbezogenen knochenkrankheiten. | |
ATE133859T1 (de) | Pharmazeutische zubereitungen mit verzögerter freisetzung zur behandlung periodontaler erkrankungen | |
DE3786893D1 (de) | Piperidinderivat zur schmerzbehandlung. | |
SE7902742L (sv) | Disubstituerade 3-cefem-4-karboxylsyraderivat samt forfarande for framstellning derav | |
ATE135914T1 (de) | Aica riboside zur prophylaktischen behandlung von krankheiten mit einer verminderten durchblutung. | |
IT8721115A0 (it) | Fitopreparato per la cura di affezioni cutanee. | |
KR900009029A (ko) | 가축병 치료용 약물을 투여하는 장치 | |
ATE65394T1 (de) | Behandlung von knochenschwund. | |
ATE79541T1 (de) | Mischung von cholecalciferol-derivaten fuer die behandlung von nierenbezogenen knochenkrankheiten. | |
IT8919216A0 (it) | Dispositivo per la cura chirurgica dell'astigmatismo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8366 | Restricted maintained after opposition proceedings | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: AUTOIMMUNE, INC., PASADENA, CALIF., US |